以前の治療後に再発した脳腫瘍に対する通常の化学療法治療(テモゾロミド)への抗がん剤セリネキサーの追加の試験
再発膠芽腫におけるセリネキサーとテモゾロミドの第 1/2 相試験
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of temozolomide followed by selinexor in recurrent glioblastoma patients as determined by dose-limiting toxicities (DLTs) and the total toxicity profile. (Phase I) II. To evaluate the efficacy of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by progression-free survival (PFS). (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate overall response rate as determined by Response Assessment in Neuro-Oncology (RANO) response criteria.
II. To evaluate the efficacy of sequentially administering temozolomide and selinexor in recurrent glioblastoma as determined by 6-month PFS (6mPFS) and overall survival (OS).
III. To validate signatures of vulnerability to predict response to selinexor through ribonucleic acid (RNA) sequencing for 6 top-scoring gene pairs, whole exome sequencing, P53, EGFR, and Mcl-1.
OUTLINE: This is a phase I, dose-escalation study of selinexor in combination with fixed dose temozolomide followed by a phase II study that compares selinexor temozolomide combination therapy vs. temozolomide monotherapy. Patients are randomized to 1 of 2 groups for the phase II part of this trial.
GROUP I (Phase II): Patients receive temozolomide orally (PO) once daily (QD) on days 1-5 of each cycle and placebo PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
GROUP II (Phase I and II): Patients receive temozolomide PO QD on days 1-5 of each cycle and selinexor PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Phase I completed as of April 2024)
Patients undergo magnetic resonance imaging (MRI) throughout the study and blood sample collection while on study.
After completion of study treatment, patients are followed up every 2 months up to 2 years.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- 募集
- Mayo Clinic Hospital in Arizona
-
コンタクト:
- Alyx B. Porter Umphrey
- 電話番号:507-538-7623
- メール:porter.alyx@mayo.edu
-
主任研究者:
- Alyx B. Porter Umphrey
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-826-4673
- メール:becomingapatient@coh.org
-
主任研究者:
- Jana L. Portnow
-
Irvine、California、アメリカ、92612
- 募集
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-8839
- メール:ucstudy@uci.edu
-
主任研究者:
- Frances E. Chow
-
La Jolla、California、アメリカ、92093
- 募集
- UC San Diego Moores Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:858-822-5354
- メール:cancercto@ucsd.edu
-
主任研究者:
- David E. Piccioni
-
Los Angeles、California、アメリカ、90033
- 募集
- USC / Norris Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:323-865-0451
-
主任研究者:
- Jacob S. Thomas
-
Los Angeles、California、アメリカ、90020
- 募集
- Keck Medicine of USC Koreatown
-
コンタクト:
- Site Public Contact
- 電話番号:213-388-0908
-
主任研究者:
- Jacob S. Thomas
-
Los Angeles、California、アメリカ、90033
- 募集
- Los Angeles General Medical Center
-
主任研究者:
- Jacob S. Thomas
-
コンタクト:
- Site Public Contact
- 電話番号:323-865-0451
- メール:uscnorrisinfo@med.usc.edu
-
Orange、California、アメリカ、92868
- 募集
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-8839
- メール:ucstudy@uci.edu
-
主任研究者:
- Frances E. Chow
-
Sacramento、California、アメリカ、95817
- 募集
- University of California Davis Comprehensive Cancer Center
-
主任研究者:
- Orwa Aboud
-
コンタクト:
- Site Public Contact
- 電話番号:916-734-3089
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- UCHealth University of Colorado Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:720-848-0650
-
主任研究者:
- Denise M. Damek
-
-
Florida
-
Coral Gables、Florida、アメリカ、33146
- 募集
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Macarena I. De La Fuente
-
Deerfield Beach、Florida、アメリカ、33442
- 募集
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Macarena I. De La Fuente
-
Jacksonville、Florida、アメリカ、32224-9980
- 募集
- Mayo Clinic in Florida
-
コンタクト:
- Site Public Contact
- 電話番号:855-776-0015
-
主任研究者:
- Sani H. Kizilbash
-
Miami、Florida、アメリカ、33136
- 募集
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Macarena I. De La Fuente
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-679-0775
- メール:ClinicalTrials@moffitt.org
-
主任研究者:
- Patrick T. Grogan
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University Hospital/Winship Cancer Institute
-
主任研究者:
- Kimberly Hoang
-
コンタクト:
- Site Public Contact
- 電話番号:404-778-1868
-
Atlanta、Georgia、アメリカ、30308
- 募集
- Emory University Hospital Midtown
-
主任研究者:
- Kimberly Hoang
-
コンタクト:
- Site Public Contact
- 電話番号:888-946-7447
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Lauren Singer
-
Orland Park、Illinois、アメリカ、60462
- 募集
- University of Chicago Medicine-Orland Park
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Lauren Singer
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- 募集
- University of Kentucky/Markey Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:859-257-3379
-
主任研究者:
- John L. Villano
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic in Rochester
-
コンタクト:
- Site Public Contact
- 電話番号:855-776-0015
-
主任研究者:
- Sani H. Kizilbash
-
-
New Jersey
-
Livingston、New Jersey、アメリカ、07039
- 募集
- Cooperman Barnabas Medical Center
-
主任研究者:
- Andrew B. Brown
-
コンタクト:
- Site Public Contact
- 電話番号:973-322-5200
-
New Brunswick、New Jersey、アメリカ、08903
- 募集
- Rutgers Cancer Institute of New Jersey
-
コンタクト:
- Site Public Contact
- 電話番号:732-235-7356
-
主任研究者:
- Andrew B. Brown
-
Newark、New Jersey、アメリカ、07101
- 募集
- Rutgers New Jersey Medical School
-
コンタクト:
- Site Public Contact
- 電話番号:732-235-7356
-
主任研究者:
- Andrew B. Brown
-
-
New York
-
Buffalo、New York、アメリカ、14263
- 積極的、募集していない
- Roswell Park Cancer Institute
-
New York、New York、アメリカ、10032
- 募集
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:212-342-5162
- メール:cancerclinicaltrials@cumc.columbia.edu
-
主任研究者:
- Peter C. Pan
-
New York、New York、アメリカ、10016
- 募集
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
コンタクト:
- Site Public Contact
- メール:CancerTrials@nyulangone.org
-
主任研究者:
- Jose R. McFaline Figueroa
-
-
North Carolina
-
Winston-Salem、North Carolina、アメリカ、27157
- 募集
- Wake Forest University Health Sciences
-
コンタクト:
- Site Public Contact
- 電話番号:336-713-6771
-
主任研究者:
- Roy E. Strowd
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- 募集
- University of Cincinnati Cancer Center-UC Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:513-584-7698
- メール:cancer@uchealth.com
-
主任研究者:
- Lalanthica V. Yogendran
-
Cleveland、Ohio、アメリカ、44195
- 募集
- Cleveland Clinic Foundation
-
主任研究者:
- David M. Peereboom
-
コンタクト:
- Site Public Contact
- 電話番号:866-223-8100
- メール:TaussigResearch@ccf.org
-
Columbus、Ohio、アメリカ、43210
- 募集
- Ohio State University Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-293-5066
- メール:Jamesline@osumc.edu
-
主任研究者:
- Pierre Giglio
-
West Chester、Ohio、アメリカ、45069
- 募集
- University of Cincinnati Cancer Center-West Chester
-
コンタクト:
- Site Public Contact
- 電話番号:513-584-7698
- メール:cancer@uchealth.com
-
主任研究者:
- Lalanthica V. Yogendran
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- University of Oklahoma Health Sciences Center
-
コンタクト:
- Site Public Contact
- 電話番号:405-271-8777
- メール:ou-clinical-trials@ouhsc.edu
-
主任研究者:
- James D. Battiste
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- 募集
- UPMC Hillman Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:412-647-8073
-
主任研究者:
- Megan Mantica
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 一時停止
- Huntsman Cancer Institute/University of Utah
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- 積極的、募集していない
- University of Virginia Cancer Center
-
Richmond、Virginia、アメリカ、23298
- 積極的、募集していない
- VCU Massey Comprehensive Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- 募集
- University of Wisconsin Carbone Cancer Center - University Hospital
-
主任研究者:
- Ankush Bhatia
-
コンタクト:
- Site Public Contact
- 電話番号:800-622-8922
- メール:clinicaltrials@cancer.wisc.edu
-
Madison、Wisconsin、アメリカ、53718
- 募集
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
主任研究者:
- Ankush Bhatia
-
コンタクト:
- Site Public Contact
- 電話番号:800-622-8922
- メール:clinicaltrials@cancer.wisc.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients must have histologically confirmed glioblastoma (IDH wild-type, MGMT promoter methylated) that has undergone resection or biopsy upon first recurrence. Recurrence at site of prior involvement is defined by histopathological evidence of viable neoplastic cells associated with any of the following: mitotic activity, increased proliferation rate, micro-endothelial proliferation, or pseudo-palisading necrosis
- Prior to resection or biopsy, patients must have measurable disease, defined as at least one bi-dimensional contrast-enhancing lesion with clearly defined margins, with 2 perpendicular diameters of at least 10 mm, visible on >= 2 axial slices
- Patients must have received first-line treatment of temozolomide plus radiotherapy
- Patients must not have received any prior therapy aside from resection or biopsy for their recurrent disease
- Age >= 18 years. Because no dosing or adverse event data are currently available on the use of selinexor (KPT-330) in combination with temozolomide in patients < 18 years of age, children are excluded from this study
- Karnofsky performance status >= 60% (Eastern Cooperative Oncology Group [ECOG] =< 2)
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 10 g/dL
- Total bilirubin =< 2 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine transaminase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) =< 3 x institutional ULN
- Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- The effects of selinexor (KPT-330) and temozolomide on the developing human fetus are unknown. For this reason and because selective nuclear export inhibitors as well as deoxyribonucleic acid (DNA) alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for 180 days after the last dose of temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of study treatment administration
- Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients who have had chemotherapy must have full recovery of organ and marrow function following the nadir of the last chemotherapy cycle
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
- Patients who are receiving any other investigational agents
- Patients who have previously received bevacizumab
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to selinexor (KPT-330) or temozolomide
- History of hypersensitivity to dacarbazine (DTIC), since both dacarbazine and temozolomide are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC)
- Patients with uncontrolled intercurrent illness
- Pregnant women are excluded from this study because selinexor (KPT-330) is a selective inhibitor of nuclear export with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with selinexor (KPT-330), breastfeeding is not allowed for mothers during treatment with selinexor (KPT-330) and for 7 days after the last dose. These potential risks may also apply to other agents used in this study
- Hospitalized patients with severe coronavirus disease of 2019 (COVID-19) who are >= 75 years old, or with a high-risk COVID-GRAM score, or with lactate dehydrogenase (LDH) > 370 (U/L) AND D-Dimer > 600 mcg/L FEU should not receive low-dose selinexor (KPT-330) pending additional results
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Group I (temozolomide)
Patients receive temozolomide PO QD on days 1-5 of each cycle and placebo PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Undergo blood sample collection
他の名前:
Undergo MRI
他の名前:
Given PO
他の名前:
Given PO |
|
実験的:Group II (temozolomide, selinexor)
Patients receive temozolomide PO QD on days 1-5 of each cycle and selinexor PO QD on days 8 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the study and blood sample collection while on study. |
Undergo blood sample collection
他の名前:
Undergo MRI
他の名前:
Given PO
他の名前:
Given PO
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recommended phase 2 dose (RP2D) (Phase I)
時間枠:Up to 28 days
|
Any eligible patient who receives at least one dose of protocol-defined therapy will be considered evaluable for dose-limiting toxicity (DLT) if either of the following occurs: (1) the patient experiences a DLT during cycle 1 of therapy; or (2) the patient receives at least 4 doses of temozolomide and 1 dose of selinexor. All other patients enrolled during the phase 1 portion of the study will be considered inevaluable for DLT and may be replaced for the purposes of establishing the RP2D. |
Up to 28 days
|
|
Progression-free survival (PFS) (Phase II)
時間枠:From randomization to date of disease progression (either progression of existing lesions or appearance of new lesions), death, or date of last contact, whichever occurs first, assessed up to 3 years
|
Patients who experience disease progression or death will be considered to have experienced a PFS-event; otherwise the patient is considered censored at last contact. |
From randomization to date of disease progression (either progression of existing lesions or appearance of new lesions), death, or date of last contact, whichever occurs first, assessed up to 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Response according to response assessment in neuro-oncology criteria (RANO) criteria
時間枠:Up to 3 years
|
A patient who is evaluated as complete response, partial response, or stable disease will be considered a RANO-responder. All other patients will be considered RANO-non-responders. Response rate will be calculated and comparisons made using categorical data methods. |
Up to 3 years
|
|
Six-month progression-free survival (PFS-6)
時間枠:At 6 months
|
Any patient considered evaluable for RANO response will be considered evaluable for PFS-6. Any evaluable patient who is considered progression free for the primary analysis will be considered a PFS-6 responder. All other evaluable patients will be considered PFS-6 non-responders. |
At 6 months
|
|
Median overall survival
時間枠:Time between the date of randomization and the date of death or date of last contact, whichever occurs first, assessed up to 3 years
|
Will be calculated from the Kaplan-Meier estimate of the probability of death as a function of time since enrollment. Ninety-five percent (95%) confidence intervals will be calculated as well. |
Time between the date of randomization and the date of death or date of last contact, whichever occurs first, assessed up to 3 years
|
|
Molecular signatures of vulnerability
時間枠:Up to 3 years
|
Will be assessed using logistic regression for the outcome measure (RANO response) and using proportional hazard regression with the biological characteristic of interest as the predictor variable for risk for PFS event. Patients considered evaluable for RANO response and PFS, respectively, will contribute to the analyses for these exploratory outcomes. Two-sided statistical testing will be employed, and a p-value of 0.05 or less will be considered as indicating significant evidence of association between the particular signature and the outcome of interest. |
Up to 3 years
|
協力者と研究者
捜査官
- 主任研究者:Jana L Portnow、City of Hope Comprehensive Cancer Center LAO
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NCI-2022-05066
- UM1CA186717 (米国 NIH グラント/契約)
- NCI-2022-05066 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- 10505 (その他の識別子:CTEP)
- PHII-222
- 10505 (その他の識別子:City of Hope Comprehensive Cancer Center LAO)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。